{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:51:14Z","timestamp":1774047074346,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T00:00:00Z","timestamp":1397779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1472-6823-14-37","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T05:39:09Z","timestamp":1397799549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies"],"prefix":"10.1186","volume":"14","author":[{"given":"Alan","family":"Sinclair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Bode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ujjwala","family":"Vijapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Usiskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Meininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,18]]},"reference":[{"key":"245_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012, 55: 1577-1596. 10.1007\/s00125-012-2534-0.","journal-title":"Diabetologia"},{"key":"245_CR2","unstructured":"Canadian Diabetes Association: Clinical Practice Guidelines. [\n                    http:\/\/guidelines.diabetes.ca\/\n                    \n                  ]"},{"key":"245_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","volume":"368","author":"GL Booth","year":"2006","unstructured":"Booth GL, Kapral MK, Fung K, Tu JV: Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006, 368: 29-36. 10.1016\/S0140-6736(06)68967-8.","journal-title":"Lancet"},{"key":"245_CR4","unstructured":"International Diabetes Federation: Global guidelines for type 2 diabetes. [\n                    http:\/\/www.idf.org\/sites\/default\/files\/IDF-Guideline-for-Type-2-Diabetes.pdf\n                    \n                  ]"},{"issue":"suppl","key":"245_CR5","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1016\/j.jcjd.2013.01.045","volume":"37","author":"GS Meneilly","year":"2013","unstructured":"Meneilly GS, Knip A, Tessier D: Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: diabetes in the elderly. Can J Diabetes. 2013, 37 (suppl): S184-S190.","journal-title":"Can J Diabetes"},{"key":"245_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1475-2840-11-122","volume":"11","author":"P Bramlage","year":"2012","unstructured":"Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschope D: Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012, 11: 122-10.1186\/1475-2840-11-122.","journal-title":"Cardiovasc Diabetol"},{"key":"245_CR7","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","volume":"365","author":"DS Budnitz","year":"2011","unstructured":"Budnitz DS, Lovegrove MC, Shehab N, Richards CL: Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011, 365: 2002-2012. 10.1056\/NEJMsa1103053.","journal-title":"N Engl J Med"},{"key":"245_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W, for the Canagliflozin DIA 2001 Study Group: Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012, 35: 1232-1238. 10.2337\/dc11-1926.","journal-title":"Diabetes Care"},{"key":"245_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenl\u00f6f","year":"2013","unstructured":"Stenl\u00f6f K, Cefalu WT, Kim K-A, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013, 15: 372-382. 10.1111\/dom.12054.","journal-title":"Diabetes Obes Metab"},{"key":"245_CR10","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G: Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013, 36: 2508-2515. 10.2337\/dc12-2491.","journal-title":"Diabetes Care"},{"key":"245_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","volume":"41","author":"B Bode","year":"2013","unstructured":"Bode B, Stenl\u00f6f K, Sullivan D, Fung A, Usiskin K: Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013, 41: 72-84. 10.3810\/hp.2013.04.1020.","journal-title":"Hosp Pract"},{"key":"245_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013, 382: 941-950. 10.1016\/S0140-6736(13)60683-2.","journal-title":"Lancet"},{"key":"245_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"JF Yale","year":"2013","unstructured":"Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G: Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013, 15: 463-473. 10.1111\/dom.12090.","journal-title":"Diabetes Obes Metab"},{"key":"245_CR14","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"F Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez F, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013, 56: 2582-2592. 10.1007\/s00125-013-3039-1.","journal-title":"Diabetologia"},{"key":"245_CR15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"JP Wilding","year":"2013","unstructured":"Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013, 67: 1267-1282. 10.1111\/ijcp.12322.","journal-title":"Int J Clin Pract"},{"key":"245_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1185\/03007995.2013.850066","volume":"30","author":"K Stenl\u00f6f","year":"2014","unstructured":"Stenl\u00f6f K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G: Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014, 30: 163-175. 10.1185\/03007995.2013.850066.","journal-title":"Curr Med Res Opin"},{"key":"245_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","volume":"14","author":"D Devineni","year":"2012","unstructured":"Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S: Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012, 14: 539-545. 10.1111\/j.1463-1326.2012.01558.x.","journal-title":"Diabetes Obes Metab"},{"key":"245_CR18","doi-asserted-by":"publisher","first-page":"E867","DOI":"10.1210\/jc.2012-4205","volume":"98","author":"D Polidori","year":"2013","unstructured":"Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P: Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013, 98: E867-E871. 10.1210\/jc.2012-4205.","journal-title":"J Clin Endocrinol Metab"},{"key":"245_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jamda.2012.04.012","volume":"13","author":"A Sinclair","year":"2012","unstructured":"Sinclair A, Morley JE, Rodriguez-Manas L, Paolisso G, Bayer T, Zeyfang A, Bourdel-Marchasson I, Vischer U, Woo J, Chapman I, Dunning T, Meneilly G, Rodriguez-Saldana J, Gutierrez Robledo LM, Cukierman-Yaffe T, Gadsby R, Schernthaner G, Lorig K: Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012, 13: 497-502. 10.1016\/j.jamda.2012.04.012.","journal-title":"J Am Med Dir Assoc"},{"key":"245_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P: Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011, 13: 669-672. 10.1111\/j.1463-1326.2011.01406.x.","journal-title":"Diabetes Obes Metab"},{"key":"245_CR21","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K: Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE. 2012, 7: e30555-10.1371\/journal.pone.0030555.","journal-title":"PLoS ONE"},{"issue":"suppl 1","key":"245_CR22","first-page":"A294","volume":"60","author":"D Polidori","year":"2011","unstructured":"Polidori D, Sakai M, Devineni D: Exposure-response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM) [abstract]. Diabetes. 2011, 60 (suppl 1): A294-","journal-title":"Diabetes"},{"issue":"suppl 1","key":"245_CR23","first-page":"A280","volume":"62","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Davies M, Dumas R, Desai M, Alba M, Capuano G, Meininger G: Effects of canagliflozin added on to basal insulin +\/- other antihyperglycemic agents in type 2 diabetes [abstract]. Diabetes. 2013, 62 (suppl 1): A280-","journal-title":"Diabetes"},{"key":"245_CR24","volume-title":"Forxiga 5 mg and 10 mg film-coated tablets","author":"Summary of Product Characteristics","year":"2012","unstructured":"Summary of Product Characteristics: Forxiga 5 mg and 10 mg film-coated tablets. 2012, Middlesex, United Kingdom: Bristol-Myers Squibb\/AstraZeneca EEIG"},{"issue":"suppl 1","key":"245_CR25","first-page":"LB19","volume":"62","author":"T Hach","year":"2013","unstructured":"Hach T, Gerich JE, Salsali A, Kim G, Hantal S, Woerle HJ, Broedl UC: Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials [abstract]. Diabetes. 2013, 62 (suppl 1): LB19-","journal-title":"Diabetes"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-14-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6823-14-37\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-14-37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-14-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T16:55:32Z","timestamp":1548176132000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/1472-6823-14-37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1186\/1472-6823-14-37","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,18]]},"assertion":[{"value":"31 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"37"}}